Freeing vaccine adjuvants from dangerous immunological dogma
- 1 February 2008
- journal article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 7 (1) , 7-10
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Vaccine adjuvants: Current state and future trendsImmunology & Cell Biology, 2004
- Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adultsVaccine, 2003
- The Danger Model: A Renewed Sense of SelfScience, 2002
- A 2-Dose Regimen of a Recombinant Hepatitis B Vaccine with the Immune Stimulant AS04 Compared with the Standard 3-Dose Regimen of Engerix-B in Healthy Young AdultsScandinavian Journal of Infectious Diseases, 2002
- Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrixVaccine, 1995
- Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunityResearch in Immunology, 1992
- The adjuvanticity of Algammulin, a new vaccine adjuvantVaccine, 1991
- Algammulin, a new vaccine adjuvant comprising gamma inulin particles containing alum: preparation and in vitro propertiesVaccine, 1991
- Immunological adjuvants: Desirable properties and side-effectsMolecular Immunology, 1991
- The adjuvanticity of gamma inulinImmunology & Cell Biology, 1988